Skip to main content

Advertisement

SpringerLink
Log in

Neurologic manifestations of the antiphospholipid syndrome: Integrating molecular and clinical lessons

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

The antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by autoantibody production and thrombosis or pregnancy morbidity. The most prevalent neurologic manifestation of APS is cerebrovascular ischemic events due to arterial thromboses. Antiphospholipid antibodies can also cause neurologic impairments unrelated to thrombosis, through antibody-cellular interactions, possibly because of a disrupted blood-brain barrier. Antiplatelet or anticoagulant therapies are currently indicated for APS-related ischemic strokes, but they remain controversial for non-thrombotic neurologic manifestations. Scant literature exists on neurologic manifestations and treatment regimens in childhood APS. Modifiable cardiac risk factors and valvular heart disease may worsen APS cerebrovascular outcomes. Adjunctive therapies (eg, statins, antimalarials, and angiotensin-converting enzyme inhibitors) warrant clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Bertolaccini ML, Khamashta MA, Hughes GR: Diagnosis of antiphospholipid syndrome. Nat Clin Pract Rheumatol 2005, 1:40–46.

    Article  PubMed  CAS  Google Scholar 

  2. Levine JS, Branch DW, Rauch J: The antiphospholipid syndrome. N Engl J Med 2002, 346:752–763.

    Article  PubMed  CAS  Google Scholar 

  3. Miyakis S, Lockshin MD, Atsumi T, et al.: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006, 4:295–306.

    Article  PubMed  CAS  Google Scholar 

  4. Pierangelli SS, Chen PP, González EB: Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr Opin Hematol 2006, 13:366–375.

    Article  Google Scholar 

  5. Hanly JG: Antiphospholipid syndrome: an overview. CMAJ 2003, 168:1675–1682.

    PubMed  Google Scholar 

  6. Lim W, Crowther MA, Eikelboom JW: Management of the antiphospholipid antibody syndrome: a systemic review. JAMA 2006, 295:1050–1057.

    Article  PubMed  CAS  Google Scholar 

  7. Kamat AV, D’Cruz DP, Hunt BJ, et al.: Managing antiphospholipid antibodies and antiphospholipid syndrome in children. Haematologica 2006, 91:1674–1680.

    PubMed  Google Scholar 

  8. Lockshin MD, Erkan D: Treatment of the antiphospholipid syndrome. N Engl J Med 2003, 349:1177–1179.

    Article  PubMed  CAS  Google Scholar 

  9. Cervera R, Khamashta MA, Font J, et al.: Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003, 82:299–308.

    Article  PubMed  Google Scholar 

  10. Merrill JT, Asherson RA: Catastrophic antiphospholipid syndrome. Nat Clin Pract Rheumatol 2006, 2:81–89.

    Article  PubMed  CAS  Google Scholar 

  11. Brandt JT, Triplett DA, Alving B, Scharrer I: Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the subcommittee on lupus anticoagulant/ antiphospholipid antibody of the scientific and standardization committee of the ISTH. Thromb Haemost 1995, 74:1185–1190.

    PubMed  CAS  Google Scholar 

  12. Galli M, Luciani D, Bertolini G, Barbui T: Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2005, 101:1827–1832.

    Article  CAS  Google Scholar 

  13. Pierangelli SS, Vega-Ostertag ME, Harris EN: Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells a pathway to targeted therapies. Thromb Res 2004, 114:467–476.

    Article  CAS  Google Scholar 

  14. Salmon JE, Girardi G, Holers VM: Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 2002, 61:46–50.

    Google Scholar 

  15. Dignat-George F, Camoin-Jau L, Sabatier F, et al.: Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost 2004, 91:667–673.

    PubMed  CAS  Google Scholar 

  16. Pierangeli SS, Vega-Ostertag ME, Raschi E, et al.: Toll-like receptor and antiphospholipid-mediated thrombosis: in vivo studies. Ann Rheum Dis 2007, 66:1327–1333.

    Article  PubMed  CAS  Google Scholar 

  17. Hulstein JJ, Lenting PJ, de Laat B, et al.: Beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood 2007, 110:1483–1491.

    Article  PubMed  CAS  Google Scholar 

  18. Meroni PL, Tincani A, Sepp N, et al.: Endothelium and the brain in CNS lupus. Lupus 2003, 12:919–928.

    Article  PubMed  CAS  Google Scholar 

  19. Abbott NJ, Mendonca LL, Dolman DE: The blood-brain barrier in systemic lupus erythematosus. Lupus 2003, 12:908–915.

    Article  PubMed  CAS  Google Scholar 

  20. Connor P, Hunt BJ: Cerebral haemostasis and antiphospholipid antibodies. Lupus 2003, 12:929–934.

    Article  PubMed  CAS  Google Scholar 

  21. Trysberg E, Nylen K, Rosengren LE. et al.: Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 2003, 48:2881–2887.

    Article  PubMed  Google Scholar 

  22. Caronti B, Calderaro C, Alessandri C, et al.: Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J Autoimmun 1998, 11:425–429.

    Article  PubMed  CAS  Google Scholar 

  23. Chapman J, Cohen-Armon M, Shoenfeld Y, et al.: Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999, 8:127–133.

    Article  PubMed  CAS  Google Scholar 

  24. Riccio A, Andreassi C, Eboli M: Antiphospholipid antibodies bind to rat cerebellar granule cells: the role of N-methyl-D-aspartate receptors. Neurosci Lett 1998, 257:116–118.

    Article  PubMed  CAS  Google Scholar 

  25. Ziporen L, Shoenfeld Y, Levy Y, et al.: Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies: a mouse model. J Clin Invest 1997, 100:613–619.

    Article  PubMed  CAS  Google Scholar 

  26. Sanna G, Bertolaccini ML, Cuadrado MJ, et al.: Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology 2003, 42:200–213.

    Article  PubMed  CAS  Google Scholar 

  27. Brey RL: Management of the neurological manifestations of APS-what do the trials tell us? Thromb Res 2004, 114:489–499.

    Article  PubMed  CAS  Google Scholar 

  28. Janhardan V, Wolf PA, Kase CS, et al.: Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attacks: the Framingham cohort and offspring study. Stroke 2004, 35:736–741.

    Article  Google Scholar 

  29. Menon S, Jameson-Shortall E, Newman SP, et al.: A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999, 42:735–741.

    Article  PubMed  CAS  Google Scholar 

  30. McLaurin E, Holliday SL, Williams P, Brey RL: Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 2005, 64:297–303.

    PubMed  CAS  Google Scholar 

  31. Jacobson MW, Rapport LJ, Keenan PA, et al.: Neuropsychological deficits associated with antiphospholipid antibodies. J Clin Exp Neuropsychol 1999, 21:251–264.

    Article  PubMed  CAS  Google Scholar 

  32. Buller HR, Agnelli G, Hull RD, et al.: Antithrombotic therapy for venous thromboem bolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004, 126(3 Suppl):401S–428S.

    Article  PubMed  CAS  Google Scholar 

  33. Rosove MH, Brewer PM: Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992, 117:303–308.

    PubMed  CAS  Google Scholar 

  34. Khamashta MA, Cudardo MJ, Mujic F, et al.: The management of thrombosis in the antiphospholipid syndrome. N Engl J Med 1995, 332:993–997.

    Article  PubMed  CAS  Google Scholar 

  35. Crowther MA, Ginsberg JS, Julian J, et al.: A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003, 349:1133–1138.

    Article  PubMed  CAS  Google Scholar 

  36. Finazzi G, Marchioli R, Brancaccio V, et al.: A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005, 3:848–853.

    Article  PubMed  CAS  Google Scholar 

  37. The APASS Writing Committee: Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004, 291:576–584.

    Article  Google Scholar 

  38. Toloza SM, Uribe AG, McGwin G, et al.: Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004, 50:3947–3957.

    Article  PubMed  Google Scholar 

  39. Akimoto T: Risk factors for recurrent thrombosis: Prospective study of a cohort of Japanese systemic lupus erythematosus. Angiology 2005, 56:601–609.

    Article  PubMed  Google Scholar 

  40. Roldan CA, Gelgand EA, Qualls CR, et al.: Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol 2005, 95:1441–1447.

    Article  PubMed  Google Scholar 

  41. Krause I, Lev S, Fraser A, et al.: Close association between valvular heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis 2005, 64:1490–1493.

    Article  PubMed  CAS  Google Scholar 

  42. Alarcon-Segovia D, Boffa MC, Branch W, et al.: Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 2003, 12:499–503.

    Article  PubMed  CAS  Google Scholar 

  43. Erkan D, Harrison MJ, Levy R, et al.: Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007, 56:2382–2391.

    Article  PubMed  CAS  Google Scholar 

  44. Chapman J, Rand JH, Brey RL, et al.: Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus 2003, 12:514–517.

    Article  PubMed  CAS  Google Scholar 

  45. Angelini L, Ravelli A, Caporali R, et al.: High prevalence of antiphospholipid antibodies in children with idiopathic cerebral ischemia. Pediatrics 1994, 94:500–503.

    PubMed  CAS  Google Scholar 

  46. Lanthier S, Kirkham FJ, Mitchell LG, et al.: Increased anticardiolipin antibody IgG titers do not predict recurrent stroke or TIA in children. Neurology 2004, 62:194–200.

    PubMed  CAS  Google Scholar 

  47. Berkun Y, Padeh S, Barash J, et al.: Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum 2006, 55:850–855.

    Article  PubMed  CAS  Google Scholar 

  48. Roubey RA: New approaches to prevention of thrombosis in the antiphospholipid syndrome: Hopes, trials and tribulations. Arthritis Rheum 2003, 48:3004–3008.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine/Neurology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229-3900, USA

    Robin L. Brey

Authors
  1. Eyal Muscal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robin L. Brey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robin L. Brey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Muscal, E., Brey, R.L. Neurologic manifestations of the antiphospholipid syndrome: Integrating molecular and clinical lessons. Curr Rheumatol Rep 10, 67–73 (2008). https://doi.org/10.1007/s11926-008-0012-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-008-0012-y

Keywords

Search

Navigation